Clinical trials in Legnano – page 12

2 907 clinical trials in Legnano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Legnano at a glance

2 907

clinical trials

Research sites1

Quick filters

2 907 trials in Legnano

Open in trial search

Pancreatic carcinoma metastatic

Recruiting

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Daraxonrasib
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Systemic scleroderma

Recruiting

Safety and Efficacy of MTX-474 in Adults with Diffuse Cutaneous Systemic Sclerosis (dcSSc) – A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Registered drug

Safety and Efficacy of MTX-474 in Adults with Diffuse Cutaneous Systemic Sclerosis (dcSSc) – A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:MTX-474
Sponsor:Mediar Therapeutics Inc.

Contact Research Centre

Parkinson's disease

Recruiting

Efficacy of intravenous prasinezumab versus placebo in Parkinson's disease patients with severe GBA mutation: a 104‑week randomized double‑blind study

Registered drug

Efficacy of intravenous prasinezumab versus placebo in Parkinson's disease patients with severe GBA mutation: a 104‑week randomized double‑blind study

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Prasinezumab
Sponsor:Universitaetsklinikum Tuebingen AöR

Contact Research Centre

Ductal adenocarcinoma of pancreas

Recruiting

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:ASP3082
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Chronic myeloid leukaemia

Recruiting

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bosutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Non-small cell lung cancer

Recruiting

A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo

A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Infliximab
Sponsor:Astrazeneca AB

Contact Research Centre

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Epoetin Alfa
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Acquired C1 inhibitor deficiency

Recruiting

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Deucrictibant
Sponsor:Pharvaris Netherlands B.V.

Contact Research Centre

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Non-small cell lung cancer

Recruiting

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Astrazeneca AB

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:AB521
Sponsor:Arcus Biosciences Inc.

Contact Research Centre

Non-small cell lung cancer stage IV+2

Recruiting

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Legnano

What the registry says about research in the country

01 Hematologic Oncology

Extensive research focusing on Multiple Myeloma treatments, including innovative therapies for relapsed and refractory cases. Studies evaluating new drug combinations and treatment approaches for better patient outcomes.

Melflufen therapy for elderly patients
Elranatamab monotherapy trials
Novel combination treatments for RRMM

Multiple ongoing trials testing various therapeutic combinations to improve survival rates.

02 Solid Tumors

Groundbreaking studies in lung cancer and breast cancer treatment, investigating novel immunotherapy combinations and targeted therapies.

Advanced NSCLC immunotherapy trials
HER2-positive breast cancer treatments
Colorectal cancer targeted therapies

Focus on personalized treatment approaches and biomarker-driven therapies.

03 Chronic Conditions

Innovative research in chronic kidney disease and HIV management, exploring new treatment strategies and medication combinations.

Non-diabetic kidney disease treatments
HIV antiretroviral therapy optimization
Ulcerative colitis interventions

Studies aimed at improving long-term patient outcomes and quality of life.

Back to Italy All countries